

Pan-Canadian Pricing Alliance: Completed Negotiations

As of April 1, 2014

34 joint negotiations have been **completed**** for the following drugs and indications:

Drug Product Brand Name (Generic Name)	Indication/Use <i>Please refer to individual jurisdictions for specific reimbursement criteria</i>
Adcetris (brentuximab)	Used to treat lymphoma
Afinitor (everolimus)	Used to treat pancreatic neuroendocrine tumours, and to treat breast cancer
Alimta (pemetrexed)	Used to treat lung cancer (new indication)
Brilinta (ticagrelor)[†]	Used with ASA to prevent atherothrombotic events in patients with acute coronary syndrome
Difidid	Used to treat Clostridium difficile
Effient (prasugrel)	Used with ASA to prevent atherothrombotic events in patients with acute coronary syndrome
Eliquis (apixaban)	Used to prevent strokes in patients with atrial fibrillation, and to prevent deep vein thrombosis
Erivedge (vismodegib)*	Used to treat metastatic basal cell carcinoma
Gilenya (fingolimod)[†]	Used to treat relapsing-remitting multiple sclerosis
Halaven (eribulin)	Used to treat breast cancer
Inlyta	Used to treat metastatic renal cell carcinoma
Jakavi (ruxolitinib)	Used to treat intermediate to high risk myelofibrosis
Kadcyla (trastuzumab emtansine)*	Used to treat HER-2 positive metastatic breast cancer
Kuvan (saproterin)[†]	Used to treat phenylketonuria
Mozobil (plerixafor)	Used in combination with <i>granulocyte colony-stimulating factor</i> to support treatment for non-Hodgkin lymphoma and multiple myeloma
Onbrez (indacaterol)[†]	Used as a bronchodilator for chronic obstructive pulmonary disease
Oralair (grass pollen allergen extract)	Used to treat allergic rhinitis with or without conjunctivitis
Perjeta (pertuzumab)	Used to treat breast cancer
Pradaxa (dabigatran)[†]	Used to prevent strokes in patients with atrial fibrillation
Seebri Breezhaler (glycopyrronium bromide)	Used to treat chronic obstructive pulmonary disease
Soliris (eculizumab)[†]	Used to treat paroxysmal nocturnal hemoglobinuria
Stribild (elvitegravir/cobicistat/emtricitabine/ tenofovir)	Used to treat HIV-1 infection in antiretroviral treatment-naïve adult patients
Sutent (sunitinib)	Used to treat pancreatic neuroendocrine tumours
Treanda (bendamustine)[†]	Used to treat non-Hodgkin lymphoma, mantle cell lymphoma, chronic lymphocytic leukemia
Tysabri (natalizumab)	Used to treat relapsing-remitting multiple sclerosis
Votrient (pazopanib)	Used to treat metastatic renal cell carcinoma
Xalkori (crizotinib)	Used to treat advanced non-small cell lung cancer
Xarelto (rivaroxaban)[†]	Used to prevent strokes in patients with atrial fibrillation, and to prevent deep vein thrombosis

Drug Product Brand Name (Generic Name)	Indication/Use <i>Please refer to individual jurisdictions for specific reimbursement criteria</i>
Xtandi (enzalutamide)	Used for castrate resistant prostate cancer
Yervoy (ipilimumab) [†]	Used to treat unresectable or metastatic melanoma
Zytiga (abiraterone)	Used to treat prostate cancer
2 drug negotiations were closed as agreements were not reached:	
Byetta (exenatide)	Used to treat Type 2 diabetes
Victoza (liraglutide)	Used to treat Type 2 diabetes

** A completed pan-Canadian negotiation refers to those for which a Letter of Intent (document which outlines the agreed upon terms and conditions for listing) has been signed between the lead jurisdiction for the negotiation and the manufacturer.

†The initial nine products negotiated through the PCPA.

* New negotiations completed since last update of February 28, 2014.

Note: Québec and Nunavut are not participating in the Pan-Canadian Pricing Alliance.